Senti Biosciences (SNTI) AI Stock Analysis

• Market Cap: $82.94M
• Dividend Yield: N/A
• Average Volume (3M): 159.64K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.76
• Revenue Growth: -100.00%
• EPS Growth: 24.59%
• Country: US
• Employees: 34
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -1.41
• Shares Outstanding: 26,081,139
• 10 Day Avg. Volume: 25,540
• 30 Day Avg. Volume: 159,639
• PEG Ratio: -0.01
• Price to Book (P/B): 0.61
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.15
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $12.00
• Price Target Upside: 277.36% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

Senti Biosciences is currently facing significant financial challenges, with ongoing losses and high leverage being the most critical issues. While technical analysis suggests some positive momentum, the overall valuation is weak due to negative earnings. However, recent corporate events, such as promising trial data and strategic leadership changes, provide a positive outlook, offering potential upside if financial stability can be improved.

Positive Factors

Analyst Recommendation

Analyst's recommendation for Senti Biosciences is a 'Buy' with a price target increased to $10.

Clinical Trial Results

The initial data from the phase I trial of SENTI-202 showed that 2 out of 3 patients achieved complete remission, which is seen as encouraging due to the link between MRD-negative CR and better outcomes in AML.

Financing

Senti additionally disclosed a $37.6 mm PIPE financing, which should support the company's continued execution on the '202 program.

Negative Factors

Clinical Trial Uncertainty

The current dataset is small and with limited follow-up, leaving some uncertainty about the durability and response factors of SENTI-202.

Financial Position

The company ended the quarter with a limited cash position of $10.5 million, which has decreased from the previous quarter.

Patient Response

There is a lack of clarity about why one patient did not respond to the treatment, particularly given the presence of TP53-mutated AML, which is difficult to treat.

Senti Biosciences Business Overview & Revenue Model

Company Description

Senti Biosciences (SNTI) is a biotechnology company that focuses on the development of next-generation cell and gene therapies. The company leverages synthetic biology to create advanced therapeutic solutions aimed at treating complex diseases, particularly in the areas of oncology and genetic disorders. Senti's core products include engineered cell therapies that are designed to be more precise, potent, and controllable than traditional approaches.

How the Company Makes Money

Senti Biosciences primarily generates revenue through partnerships, collaborations, and licensing agreements with larger pharmaceutical companies. These agreements often involve upfront payments, milestone payments, and royalties based on the successful development and commercialization of therapies using Senti's technology platforms. Additionally, the company may receive government grants and funding from research institutions to support its innovative research and development efforts. Another potential revenue stream includes the direct commercialization of its proprietary cell and gene therapies, although this is typically contingent upon successful clinical trials and regulatory approval.

Senti Biosciences Financial Statement Overview

Summary

Senti Biosciences is experiencing financial instability with consistent net losses, negative cash flow, and high leverage. The company is struggling with revenue generation and maintaining a positive cash position, which poses significant risks to its financial health.

Income Statement

Senti Biosciences has faced significant challenges in profitability, as indicated by consistent net losses over the years. The revenue growth has been erratic, with a decline in recent years. The company’s gross profit margin is negative, and it has not been able to generate positive EBIT or EBITDA, largely due to high operational expenses. The lack of revenue and persistent losses suggest financial instability in the short term.

Balance Sheet

The balance sheet shows a weak financial position with a consistently negative stockholders' equity until 2024, indicating high leverage. The debt-to-equity ratio is unfavorable due to the negative equity in prior years, although it has improved slightly as of the latest data. The equity ratio is low, suggesting reliance on debt financing, which poses risks if revenue does not improve.

Cash Flow

Cash flow from operations is negative, reflecting the ongoing struggle to generate cash from core activities. The free cash flow is also negative, indicating the company is burning cash and may require additional financing to sustain operations. Despite capital raising efforts, the cash position remains under pressure, with operating cash flow not covering net losses, which is a concerning sign for liquidity.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	2.56M	4.29M	2.29M	394.00K
	Gross Profit
0.00	-2.68M	366.00K	-719.00K	-15.56M
	EBIT
-61.04M	-92.73M	-70.63M	-40.45M	-24.69M
	EBITDA
-61.04M	-61.34M	-70.63M	-39.68M	-22.71M
	Net Income Common Stockholders
-52.79M	-92.92M	-58.21M	-55.32M	-19.86M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
48.28M	35.93M	98.56M	56.03M	30.54M
	Total Assets
97.84M	119.48M	180.79M	96.70M	48.34M
	Total Debt
33.54M	37.67M	37.09M	22.73M	14.05M
	Net Debt
-14.74M	1.74M	-20.53M	-33.30M	-16.49M
	Total Liabilities
72.19M	52.57M	53.53M	208.16M	107.06M
	Stockholders Equity
25.65M	66.91M	127.26M	-111.46M	-58.71M
Cash Flow		Free Cash Flow
-41.42M	-64.43M	-76.27M	-40.18M	-25.33M
	Operating Cash Flow
-41.40M	-52.40M	-34.90M	-34.63M	-24.17M
	Investing Cash Flow
34.00K	30.08M	-81.96M	-5.54M	11.36M
	Financing Cash Flow
53.73M	779.00K	118.55M	68.44M	38.05M

Senti Biosciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.18
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNTI, the sentiment is Negative. The current price of 3.18 is below the 20-day moving average (MA) of 3.53, below the 50-day MA of 3.46, and below the 200-day MA of 3.30, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 45.44 is Neutral, neither overbought nor oversold. The STOCH value of 24.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SNTI.

Senti Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.19B	3.04	-44.64%	2.82%	16.45%	-0.53%
EDIT	51 Neutral	$124.73M	―	-140.82%	―	-48.37%	-44.70%
SNTI	47 Neutral	$82.94M	―	-116.63%	―	-100.00%	24.59%
CCCC	41 Neutral	$109.35M	―	-45.55%	―	98.56%	37.97%
RAPT	39 Underperform	$110.92M	―	-75.60%	―	―	-2.29%
TIL	34 Underperform	$95.97M	―	-44.50%	―	―	52.54%

Senti Biosciences Corporate Events

Senti Biosciences Unveils Promising Phase 1 Trial Data

On April 28, 2025, Senti Biosciences announced preliminary data from a Phase 1 clinical trial of SENTI-202, a novel CAR NK cell therapy for relapsed/refractory hematologic malignancies, including AML. This data, presented at the AACR Annual Meeting 2025, showed positive preliminary efficacy and supports the potential of SENTI-202 as a first-in-class treatment option, which could significantly impact the company’s market positioning and offer new hope for stakeholders dealing with these aggressive cancers.

Spark’s Take on SNTI Stock

According to Spark, TipRanks’ AI Analyst, SNTI is a Neutral.

Senti Biosciences faces significant financial instability, as reflected in its low financial performance score. Despite short-term positive market momentum, the company’s valuation remains unattractive due to negative earnings. Recent corporate appointments are positive, but insufficient to offset underlying financial weaknesses.

To see Spark’s full report on SNTI stock, click here.

Senti Biosciences Expands Board with New Appointment

On March 7, 2025, Senti Biosciences, Inc. expanded its Board of Directors by appointing Feng Hsiung as a Class III director, increasing the number of board members from six to seven. Mr. Hsiung, with a rich background in business, finance, and investment, is expected to serve until the 2028 annual stockholders meeting, subject to election in 2025. Additionally, the company amended its 2022 Inducement Plan, adding 500,000 shares for new employee inducements, and revised its Non-Employee Director Compensation Policy to attract and retain qualified board members. The changes reflect Senti Biosciences’ strategic efforts to strengthen its governance and incentivize new talent.

Senti Biosciences Appoints New CFO Jay Cross

On February 23, 2025, Senti Biosciences announced the appointment of Jay Cross as the new Chief Financial Officer, effective March 3, 2025. Cross, with extensive experience in financial leadership roles, including at Sonnet BioTherapeutics, will oversee the company’s financial strategy and operations to support its growth and clinical development. This strategic hire, alongside the addition of Faraz Siddiqui as Senior Vice President of Technical Operations, is expected to bolster Senti Bio’s leadership team as it advances its clinical pipeline and manufacturing capabilities, particularly in oncology cell therapy.

Senti Biosciences Renews Consulting Agreement with Yvonne Li

On January 31, 2025, the Consulting Agreement between Senti Biosciences, Inc. and Yvonne Li, the Interim Chief Financial Officer, expired. Subsequently, Ms. Li ceased to serve as the company’s principal financial and accounting officer. However, on February 5, 2025, a new consulting agreement was established, allowing Ms. Li to continue as a consultant to assist with the transition of her duties until March 31, 2025.